Hytrin (Terazosin Hydrochloride Dihydrate)

Terazosin works by selectively blocking alpha‑1 adrenergic receptors on vascular and prostatic smooth muscle. This blockade prevents norepinephrine‑mediated contraction, leading to vasodilation that reduces blood pressure and to relaxation of the prostate and bladder neck, which eases urinary obstruction.

The dosage of Hytrin is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber determines the starting dose, titration schedule, and maintenance dose, following current clinical guidelines and the product label.

Hytrin is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It should be used in pregnancy or while breastfeeding only if the potential benefit justifies any possible risk to the fetus or infant.

To request Hytrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hytrin (terazosin) shares the same class mechanism as other alpha‑1 antagonists such as doxazosin and tamsulosin. Compared with tamsulosin, terazosin has a longer half‑life and is often used for both hypertension and BPH, whereas tamsulosin is more selective for prostate tissue and is primarily indicated for BPH.

Hytrin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use it after the expiration date printed on the packaging.

Hytrin is taken orally, usually once daily at the same time each day. The tablet should be swallowed whole with a full glass of water and can be taken with or without food, unless the prescriber advises otherwise.

The most serious risks include severe hypotension, which can lead to fainting or shock, and priapism, a prolonged painful erection that requires urgent medical care. Rarely, patients may experience anaphylactic reactions or angioedema, which also demand immediate attention.

Hytrin should be avoided in patients with known hypersensitivity to terazosin or any component of the formulation, in those with severe orthostatic hypotension, and in individuals taking PDE5 inhibitors for erectile dysfunction due to the risk of dangerous blood‑pressure falls.